Clinical Trials Logo

Filter by:
NCT ID: NCT02804087 Terminated - Hypertension Clinical Trials

Controlling And Lowering Blood Pressure With the MobiusHDTM Device

CALM-START
Start date: August 24, 2017
Phase: N/A
Study type: Interventional

To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.

NCT ID: NCT02795325 Terminated - Clinical trials for Primary Hyperoxaluria Type 1

A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

Start date: May 13, 2016
Phase: Phase 1
Study type: Interventional

A phase 1 study of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1) to determine the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics (PD) effects of DCR-PH1 administered via-intravenous infusion (IV)

NCT ID: NCT02793349 Terminated - Ischemia Clinical Trials

The ABSORB Bioresorbable Scaffold Below the Knee (BTK) Study

Start date: June 2015
Phase: N/A
Study type: Interventional

ABSORB BTK Study: A prospective, multicenter, controlled clinical evaluation of the use of a bioresorbable drug eluting stent in the arterial vasculature below the knee

NCT ID: NCT02783573 Terminated - Alzheimer's Disease Clinical Trials

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

DAYBREAK-ALZ
Start date: July 1, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.

NCT ID: NCT02780180 Terminated - Heart Failure Clinical Trials

QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF

QUID-HF
Start date: June 2016
Phase: Phase 2
Study type: Interventional

Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction. A new therapeutic approaches by preventing activation of the brain neuromodulatory pathway, may lead to improve HF. QCG001 is a prodrug of EC33, a aminopeptidase A (APA) inhibitor. QCG001 has been shown to be an antihypertensive agent in animal models. This study investigates the safety and efficacy of QGC001 in HF patients.

NCT ID: NCT02775006 Terminated - Clinical trials for Carcinoma, Non-small Cell Lung

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Start date: October 14, 2016
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the effect of docetaxel monotherapy and the combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma.

NCT ID: NCT02764229 Terminated - Colitis, Ulcerative Clinical Trials

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Start date: November 1, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to allow subjects completing study LYC-30937-2001 the opportunity to receive LYC-30937-EC 25 mg.

NCT ID: NCT02757157 Terminated - Clinical trials for Pulmonary Disease, Chronic Obstructive

Comparison of Walking in Water and on Land in People With Chronic Obstructive Pulmonary Disease (COPD)

Start date: October 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the metabolic load during a single session of moderate intensity walking in water compared to walking on land (over-ground) in people with chronic obstructive pulmonary disease (COPD) who are normal weight and obese, compared with peak exercise metabolic response. The hypothesis is that the metabolic load of walking at a moderate intensity in water will be greater than walking on land.

NCT ID: NCT02749071 Terminated - Clinical trials for Gastroesophageal Reflux

An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux

Start date: May 2016
Phase: N/A
Study type: Interventional

The purpose of this investigation is to demonstrate the safety and effectiveness of Lower Esophageal Sphincter (LES) Stimulation System in treating gastroesophageal reflux disease (GERD). This investigation is a multicenter, randomized, double-blind, sham-controlled study. After the implant procedure, subjects will be randomized to either the Treatment Group (immediate stimulation) or Control Group (delayed stimulation) for six months followed by an additional open-label phase in which all subjects will receive electrical stimulation. Subjects continue on stimulation treatment in an extended open-label follow-up phase through 5 years post-stimulation.

NCT ID: NCT02745119 Terminated - Geographic Atrophy Clinical Trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

Start date: July 21, 2016
Phase: Phase 3
Study type: Interventional

This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who received investigational lampalizumab, as well as lampalizumab-naive participants exposed to sham comparator. All participants will receive open-label lampalizumab in the present study.